Publicacions
El coneixement generat a IrsiCaixa es comparteix amb la comunitat científica a través de la publicació d’articles a revistes científiques d’alt impacte.
Analysis of neurocognitive function and CNS endpoints in the PROTEA trial: darunavir/ritonavir with or without nucleoside analogues.
Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection.
Classification models for neurocognitive impairment in HIV infection based on demographic and clinical variables.
Sequence variations in HIV-1 p24 Gag-derived epitopes can alter binding of KIR2DL2 to HLA-C*03:04 and modulate primary natural killer cell function.
Transient increment of HTLV-2 proviral load in HIV-1-co-infected patients during treatment intensification with raltegravir.
Cytomegalovirus replication in semen is associated with higher levels of proviral HIV DNA and CD4+ T cell activation during antiretroviral treatment.
Improved prediction of salvage antiretroviral therapy outcomes using ultrasensitive HIV-1 drug resistance testing.
Detection of resistance mutations and CD4 slopes in individuals experiencing sustained virological failure.
Galectin-8 elicits pro-inflammatory activities in the endothelium.
Cell cycle control and HIV-1 susceptibility are linked by CDK6-dependent CDK2 phosphorylation of SAMHD1 in myeloid and lymphoid cells.